Vertaling van "Malignancy the cervix " (Engels → Frans) :

TERMINOLOGIE

malignancy of the cervix
tumeur maligne du col de l'utérus

invasive cervical cancer | invasive cervical carcinoma | invasive cervix cancer | invasive cervix carcinoma | invasive carcinoma of the uterine cervix | invasive cancer of the uterine cervix
cancer invasif du col de l'utérus | cancer invasif du col utérin | carcinome invasif du col utérin | cancer cervical invasif | carcinome cervical invasif

in situ cervical cancer | in situ cervical carcinoma | in situ cervix cancer | in situ cervix carcinoma | in situ carcinoma of the uterine cervix | in situ cancer of the uterine cervix
cancer in situ du col de l'utérus | cancer in situ du col utérin | carcinome in situ du col utérin

cervical cancer | cancer of the uterine cervix | carcinoma of the uterine cervix | uterine cervical cancer | uterine cervix cancer | uterine cervical carcinoma | uterine cervix carcinoma
cancer du col de l'utérus | cancer du col utérin

adenocarcinoma in situ of the cervix | AIS of the cervix
adénocarcinome in situ du col utérin | ACIS du col utérin [Abbr.]

A rare subtype of mixed epithelial-mesenchymal tumour, often presenting as a large, exophytic polypoid lesion, which may extend through the cervix, composed of benign or atypical epithelium and low-grade malignant stroma. It usually presents with dys
adénosarcome du corps de l'utérus

atresia of the external os of the cervix
agglutination du col

malignant mesothelioma of the pleura [ malignant pleural mesothelioma ]
mésothéliome pleural malin [ fibrosarcome géant de la plèvre ]

A rare type of small bowel malignancy, originating in the smooth muscle cells within the muscularis propria or the muscularis mucosa, most often found in the jejunum, and presenting with gastrointestinal bleeding and anemia and sometimes with other n
léiomyosarcome de l'instestin grêle

An extremely rare malignant epithelial tumor of the small intestine (most often localized in the duodenum). Presenting symptoms are often nonspecific, such as weight loss, epigastric pain, anorexia, weakness, fatigue, vomiting and abdominal distensio
carcinome épidermoïde de l'intestin grêle

IN-CONTEXT TRANSLATIONS

Presence, or previous history, of malignant disease, except for primary basal cell carcinoma, carcinoma in situ of the uterine cervix, and some primary tumours of the central nervous system that have to be evaluated according to scientific evidence.
Présence ou antécédents de maladie maligne, à l'exception du carcinome basocellulaire primitif, du carcinome in situ du col utérin et de certaines tumeurs primitives du système nerveux central qui doivent être évaluées à la lumière des connaissances scientifiques.

3. Presence or previous history of malignant disease, except for primary basal cell carcinoma, carcinoma in situ of the uterine cervix, and some primary tumours of the central nervous system that have to be evaluated according to the current consensus document of the Council of Europe ‘Standardisation of organ donor screening to prevent transmission of neoplasic diseases’.
Présence ou antécédents de maladie maligne, à l'exception du carcinome basocellulaire primitif, du carcinome in situ du col utérin et de certaines tumeurs primitives du système nerveux central qui doivent être évaluées à la lumière du document de consensus actuel du Conseil de l'Europe intitulé "Normaliser le dépistage chez les donneurs pour prévenir la transmission des maladies néoplastiques".

3. Presence or previous history of malignant disease, except for primary basal cell carcinoma, carcinoma in situ of the uterine cervix, and some primary tumours of the central nervous system that have to be evaluated according to the current consensus document of the Council of Europe "Standardisation of organ donor screening to prevent transmission of neoplasic diseases".
3) Présence ou antécédents de maladie maligne, à l'exception du carcinome basocellulaire primitif, du carcinome in situ du col utérin et de certaines tumeurs primitives du système nerveux central qui doivent être évaluées à la lumière du document de consensus actuel du Conseil de l'Europe intitulé "Normaliser le dépistage chez les donneurs pour prévenir la transmission des maladies néoplastiques".